INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 GFR 1.99)

	77		10624389
			2003-07-22
	First Named Inventor Mark		C. Estes
	Art Unit		3763
	Examiner Name	Matth	ew F. DeSanto
	Attorney Docket Number		PF01022US

U.S.PATENTS Remove								
Examiner Initial*	r Cite No Patent Number		Kind Code <sup>1</sup> Issue Date		Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear		
	1	5284140		1994-02-08	Allen et al.			
	2	5299571		1994-04-05	Mastrototaro			
	3	5307263		1994-04-26	Brown			
	4	5317506		1994-05-31	Coutre et al.			
	5	5319363		1994-06-07	Welch et al.			
	6	5320725		1994-06-14	Gregg et al.			
	7	5322063		1994-06-21	Allen et al.			
	8	5338157		1994-08-16	Blomquist			

	Application Number		10624389	
	Filing Date		2003-07-22	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor Mark		C. Estes	
(Not for submission under 37 CFR 1.99)	Art Unit		3763	
(Not for Submission under or or it issue	Examiner Name	Matth	ew F. DeSanto	
	Attorney Docket Number PF01022US			

9	5339821	1994-08-23	Fujimoto	
10	5341291	1994-08-23	Roizen et al.	
11	5350411	1994-09-27	Ryan et al.	
12	5356786	1994-10-19	Heller et al.	
13	5357427	1994-10-18	Langen et al.	
14	5364346	1994-11-15	Schrezenmeir	
15	5368562	1994-11-29	Blomquist et al.	
16	5370622	1994-12-06	Livingston	
17	5371687	1994-12-06	Holmes, II et al.	
18	5376070	1994-12-27	Purvis et al.	
19	5390671	1995-02-21	Lord et al.	

	Application Number		10624389	
	Filing Date		2003-07-22	
INFORMATION DISCLOSURE	First Named Inventor Mark		C. Estes	
STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)	Art Unit		3763	
( Not for Submission under or or it 1.50)	Examiner Name Matth		ew F. DeSanto	
	Attorney Docket Number		PF01022US	

20	5391250	1995-02-21	Cheney, II et al.	
21	5403700	1995-04-04	Heller et al.	
22	5411647	1995-05-02	Johnson et al.	
23	5417222	1995-05-23	Dempsey et al.	
24	5429602	1995-07-04	Hauser	
25	5437634	1995-08-01	Amano	
26	5464392	1995-11-07	Epstein et al.	
27	5472317	1995-12-05	Field et al.	
28	5478211	1995-12-26	Dominiak et al.	
29	5482446	1996-01-09	Wiliamson et al.	
30	5482473	1996-01-09	Lord et al.	

31	5485408	1996-01-16	Blomquist	
32	5497772	1996-03-12	Schulman et al.	
33	5499243	1996-03-12	Hall	
34	5507288	1996-04-16	Bocker et al.	
35	5543326	1996-08-06	Heller et al.	
36	5545191	1996-08-13	Mann et al.	
37	5558640	1996-09-24	Pfeiler et al.	
38	5569186	1996-10-29	Lord et al.	
39	5569187	1996-10-29	Kaiser	
40	5573506	1996-11-12	Vasko	
41	5582593	1996-12-10	Hultman	

#### 

	42	5584814		1996-12-17	Schuster et al.			
	43	5586553		1996-12-24	Halili et al.			
	44	5593390		1997-01-14	Castellano et al.			
	45	5593852		1997-01-14	Heller et al.			
	46	5594638		1997-01-14	ISF			
	47	5609060		1997-03-11	Dent			
	48	5609575		1997-03-11	Larson et al.			
	49	5616124		1997-04-01	Hague et al.			
	50	5620312		1997-04-15	Hyman et al.			
If you wisl	h to a	dd additional U.S. Pater			ease click the Add button.		Add Remove	
			U.S.P	ATENT APPER	DATION FUBLICATIONS	_		
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Releva		Lines where ges or Relevant

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10624389	
Filing Date		2003-07-22	
First Named Inventor	Mark C. Estes		
Art Unit		3763	
Examiner Name	Matth	ew F. DeSanto	
Attorney Docket Number		PF01022US	

Date Considered

	1								
If you wis	h to a	dd additional U.S. Publ	ished Application	citatio	n information p	please click the Add butte	on. Add		
			FOREIG	GN PAT	TENT DOCUM	IENTS	Remove		
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> j	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	TS	
	1								
If you wis	h to a	dd additional Foreign P	atent Document	citation	information pl	lease click the Add butto	n Add		
			NON-PATE	NT LITE	RATURE DO	CUMENTS	Remove		
Examiner Cite Initials* Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.								T5	
	1								
If you wis	If you wish to add additional non-patent literature document citation information please click the Add button Add								

Take Not Code of 1897/0 Pend Documents of your USETO.000 on METS 9510.6. To find often believed the document, by the her-befor code (NOC) Second of 73.3. "To hyperine plant of controls, the included of the year of the region of the Deposer must provide the serial number of the plant of beautiful observed by the approvide symbols are advanted on the document under NOTO Second of 17.6 if you have of the plant observed the plant of t

EXAMINER SIGNATURE

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Signature

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

Application Number		10624389		
Filing Date		2003-07-22		
First Named Inventor	Mark C. Estes			
Art Unit		3763		
Examiner Name	Matth	ew F. DeSanto		
Attorney Docket Number		PF01022US		

#### CERTIFICATION STATEMENT

Please see 3	7 CFR	1.97 and	1.98 to make th	e appropriate selection(s):
--------------	-------	----------	-----------------	-----------------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 37 CFF 1.37(e)(1).

### OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(e).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- \_ ...

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_				
	Signature	/Vivian S. Shin/	Date (YYYY-MM-DD)	2007-06-12
	Name/Print	Vivian S. Shin	Registration Number	43 919

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P.O. 8bx 1449, Alexandriv, V.S. 2311-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bx 1459, Alexandriva, V.S. 2311-1450.

## Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral purpuses for which the information is used by the U.S. Patient and Trademan Colline is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested region of the patient of the patient application of the patient application of the patient activities, which may result in farministion of proceedings or 4 anahoroment of the application of the patients of the pa

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record perfains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be discbesed, as a routine use, to the Administrator, General Services, or hisher designed, cuting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
  application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
  disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
  which became abandoned or in which the proceedings were terminated and which application is referenced by either a
  published application, an application open to public inspections or as issued patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.